Vascular calcification in chronic kidney disease: Are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?

Nephrology Dialysis Transplantation

Volumn 29, Issue 7, 2014, Pages 1275-1284

  Liabeuf, Sophie ^a,b   Okazaki, Hirokazu ^a   Desjardins, Lucie ^a,b   Fliser, Danilo ^c   Goldsmith, David ^d   Covic, Adrian ^e   Wiecek, Andrzej ^f   Ortiz, Alberto ^g   Martinez Castelao, Alberto ^h   Lindholm, Bengt ⁱ   Suleymanlar, Gultekin ^j   Mallamaci, Francesca ^k   Zoccali, Carmine ^k   London, Gerard ^l   Massy, Ziad A ^a,m  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g Section of Nephrology   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j AKDENIZ UNIVERSITY   (Turkey)

^k Nephrology Dialysis and Transplantation Unit   (Italy)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m HÔPITAL AMBROISE PARÉ   (France)

more..

Author keywords

Biomarkers; Chronic kidney disease; Vascular calcification

Indexed keywords

BIOLOGICAL MARKER; FETUIN A; FIBROBLAST GROWTH FACTOR 23; MAGNESIUM; MATRIX GLA PROTEIN; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHATE; PYROPHOSPHATE; UNCLASSIFIED DRUG;

AGE; BLOOD VESSEL CALCIFICATION; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CORONARY ARTERY CALCIFICATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH HAZARD; HUMAN; IN VITRO STUDY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL ARTERY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; CHRONIC KIDNEY DISEASE; VASCULAR CALCIFICATION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84903841326     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft368     Document Type: Review

References (126)

1. Jono S, Shioi A, Ikari Y et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006.; 24: 176-181
2. Temmar M, Liabeuf S, Renard C et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010.; 28: 163-169
3. Rennenberg RJ, Kessels AG, Schurgers LJ et al. Vascular calcifications as a marker of increased cardiovascular risk: A meta-Analysis. Vasc Health Risk Manag 2009.; 5: 185-197
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009.; 76: S1-130
5. Demer LL, Tintut Y. Vascular calcification: Pathobiology of a multifaceted disease. Circulation 2008.; 117: 2938-2948
6. McCullough PA, Chinnaiyan KM. Annual progression of coronary calcification in trials of preventive therapies: A systematic review. Arch Intern Med 2009.; 169: 2064-2070
7. Raggi P, Bellasi A. Clinical assessment of vascular calcification. Adv Chronic Kidney Dis 2007.; 14: 37-43
8. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007.; 167: 879-885
9. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005.; 16: 520-528
10. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-Analysis. JAMA 2011.; 305: 1119-1127
11. Chen NX, O'Neill KD, Duan D et al. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002.; 62: 1724-1731
12. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000.; 87: E10YE17
13. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004.; 15: 2857-2867
14. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003.; 361: 827-833
15. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009.; 20: 381-387
16. Ribeiro S, Ramos A, Brandao A et al. Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998.; 13: 2037-2040
17. Neven E, Dams G, Postnov A et al. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 2009.; 24: 1790-1799
18. Nikolov IG, Joki N, Nguyen-Khoa T et al. Lanthanum carbonate, like sevelamer- HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012.; 27: 505-513
19. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremiaenhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005.; 112: 2875-2882
20. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002.; 62: 245-252
21. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calciumbased phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011.; 57: 422-431
22. Toussaint ND, Lau KK, Polkinghorne KR et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011.; 16: 290-298
23. Linefsky JP, O'Brien KD, Katz R et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: The cardiovascular health study. J Am Coll Cardiol 2011.; 58: 291-297
24. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007.; 72: 1130-1137
25. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin J Am Soc Nephrol 2012.; 7: 487-493
26. Navaneethan SD, Palmer SC, VecchioMet al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011.; 2: CD006023
27. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012.; 23: 1407-1415
28. Drueke TB, Massy ZA. Phosphate binders in CKD: Bad news or good news? J Am Soc Nephrol 2012.; 23: 1277-1280
29. Zisman AL, Wolf M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 2010.; 19: 335-342
30. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007.; 20: 302-308
31. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-Associated hyperparathyroidism yet increases mortality. J Clin Invest 2012.; 122: 2543-2553
32. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997.; 390: 45-51
33. Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012.; 125: 2243-2255
34. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009.; 119: 2545-2552
35. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011.; 305: 2432-2439
36. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 2012.; 27: 2650-2657
37. Nasrallah MM, El-Shehaby AR, Salem MM et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010.; 25: 2679-2685
38. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant 2009.; 24: 948-955
39. Tamei N, Ogawa T, Ishida H et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb 2011.; 18: 217-223
40. Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2011.; 7: 2017-2025
41. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006.; 17: 1506-1513
42. Schoppet M, Hofbauer LC, Brinskelle-Schmal N et al. Serum Level of the Phosphaturic Factor FGF23 Is Associated with Abdominal Aortic Calcification in Men: The STRAMBO Study. J Clin Endocrinol Metab 2012.; 4: E575YE583
43. Moreno JA, Izquierdo MC, Sanchez-Nino MD et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 2011.; 22: 1315-1325
44. Thurston RD, Larmonier CB, Majewski PM et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology 2009.; 138: 1384-1394, 94 e1-2
45. Roos M, Lutz J, Salmhofer H et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008.; 68: 660-665
46. Srivaths PR, Silverstein DM, Leung J et al. Malnutrition- inflammationcoronary calcification in pediatric patients receiving chronic hemodialysis. Hemodial Int 2010.; 14: 263-269
47. Morena M, Jaussent I, Halkovich A et al. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One 2012.; 7: E36175
48. Scialla JJ, Lau WL, Reilly MP et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013.; 6: 1159-1168
49. Seiler S, Wen M, Roth HJ et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2012.; 83: 121-128
50. Drueke TB, Massy ZA. Circulating Klotho levels: Clinical relevance and relationship with tissue Klotho expression. Kidney Int 2012.; 83: 13-15
51. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKDMBD therapy? Clin J Am Soc Nephrol 2011.; 5: 286-291
52. Burnett SM, Gunawardene SC, Bringhurst F et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006.; 21: 1187-1196
53. Isakova T, Barchi-Chung A, Enfield G et al. Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23 Levels in CKD. Clin J Am Soc Nephrol 2013.; 6: 1009-1018
54. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cellbinding sequence. Proc Natl Acad Sci U S A 1986.; 83: 8819-8823
55. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993.; 7: 1475-1482
56. Steitz SA, Speer MY, McKee MD et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002.; 161: 2035-2046
57. Golledge J, McCann M, Mangan S et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004.; 35: 1636-1641
58. Fitzpatrick LA, Severson A, Edwards WD et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994.; 94: 1597-1604
59. O'Brien ER, Garvin MR, Stewart DK et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994.; 14: 1648-1656
60. Ikeda T, Shirasawa T, Esaki Y et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993.; 92: 2814-2820
61. Abdel-Azeez HA, Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: Association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal 2010.; 24: 201-206
62. Aryan M, Kepez A, Atalar E et al. Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. J Bone Miner Metab 2009.; 27: 591-597
63. Ohmori R, Momiyama Y, Taniguchi H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003.; 170: 333-337
64. Nitta K, Ishizuka T, Horita S et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 2001.; 89: 455-458
65. Barreto DV, Lenglet A, Liabeuf S et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract 2011.; 117: C363Yc372
66. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000.; 275: 20197-20203
67. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997.; 89: 309-319
68. Hofbauer LC, Khosla S, Dunstan CR et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000.; 15: 2-12
69. Baud'huin M, Duplomb L, Ruiz Velasco C et al. Key roles of the OPGRANK- RANKL system in bone oncology. Expert Rev Anticancer Ther 2007.; 7: 221-232
70. Abedin M, Omland T, Ueland T et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007.; 99: 513-518
71. Jono S, Ikari Y, Shioi A et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002.; 106: 1192-1194
72. Anand DV, Lahiri A, Lim E et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006.; 47: 1850-1857
73. Jung CH, Lee WY, Kim SY et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 2009.; 47: 145-152
74. Morena M, Dupuy AM, Jaussent I et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009.; 24: 3389-3397
75. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004.; 19: 1886-1889
76. Ozkok A, Caliskan Y, Sakaci T et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 2012.; 7: 965-973
77. Wei T, Wang M, Gan LY et al. Relationship of sRANKL level and vascular calcification score to cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009.; 28: 342-345
78. Chasseraud M, Liabeuf S, Mozar A et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Ther Apher Dial 2011.; 15: 140-146
79. Price PA, UristMR, Otawara Y.Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983.; 117: 765-771
80. Fraser JD, Otawara Y, Price PA. 1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines. J Biol Chem 1988.; 263: 911-916
81. Proudfoot D, Skepper JN, Shanahan CM et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 1998.; 18: 379-388
82. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002.; 277: 4388-4394
83. Ketteler M, Wanner C, Metzger T et al. Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 2003.; 63: S84YS87
84. Koos R, Krueger T, Westenfeld R et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009.; 101: 706-713
85. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997.; 386: 78-81
86. Schurgers LJ, Teunissen KJ, Knapen MH et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005.; 25: 1629-1633
87. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008.; 118: 1748-1757
88. Schlieper G, Westenfeld R, Kruger T et al. Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD. J Am Soc Nephrol 2011.; 22: 387-395
89. Hermans MM, Vermeer C, Kooman JP et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 2007.; 25: 395-401
90. Cranenburg EC, Brandenburg VM, Vermeer C et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 2009.; 101: 359-366
91. Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008.; 45: 427-436
92. O'Donnell CJ, Shea MK, Price PA et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol 2006.; 26: 2769-2774
93. Jono S, Ikari Y, Vermeer C et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004.; 91: 790-794
94. Parker BD, Schurgers LJ, Vermeer C et al. The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study. Atherosclerosis 2009.; 210: 320-325
95. Schurgers LJ, Barreto DV, Barreto FC et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin J Am Soc Nephrol 2010.; 5: 568-575
96. Westenfeld R, Krueger T, Schlieper G et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am J Kidney Dis 2012.; 59: 186-195
97. Shea MK, O'Donnell CJ, Hoffmann U et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009.; 89: 1799-1807
98. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005.; 16: 2920-2930
99. Chen NX, O'Neill KD, Chen X et al. Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. Am J Physiol Renal Physiol 2007.; 292: F599YF606
100. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans- Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003.; 112: 357-366
101. El-Shehaby AM, Zakaria A, El-Khatib M et al. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest 2010.; 70: 575-582
102. Wang AY, Woo J, Lam CW et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005.; 20: 1676-1685
103. Jung HH, Baek HJ, Kim SW. Fetuin-A, coronary artery calcification and outcome in maintenance hemodialysis patients. Clin Nephrol 2011.; 75: 391-396
104. Emoto M, Mori K, Lee E et al. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism 2009.; 59: 873-878
105. Mori K, Ikari Y, Jono S et al. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis 2010.; 21: 281-285
106. Ix JH, Chertow GM, Shlipak MG et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007.; 115: 2533-2539
107. Mehrotra R, Westenfeld R, Christenson P et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int 2005.; 67: 1070-1077
108. Mikami S, Hamano T, Fujii N et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res 2008.; 31: 1163-1170
109. Hamano T, Matsui I, Mikami S et al. FetuinYmineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010.; 21: 1998-2007
110. Bennett RM, Lehr JR, McCarty DJ. Factors affecting the solubility of calcium pyrophosphate dihydrate crystals. J Clin Invest 1975.; 56: 1571-1579
111. Louvet L, Buchel J, Steppan S et al. Magnesium prevents phosphateinduced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013.; 28: 869-878
112. Gorgels TG, Waarsing JH, de Wolf A et al. Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med (Berl) 2010.; 88: 467-475
113. Schwille PO, Schmiedl A, Schwille R et al. Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat - differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali. Biomed Pharmacother 2003.; 57: 88-97
114. Van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. Lab Anim 1998.; 32: 483-491
115. Ishimura E, Okuno S, Kitatani K et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007.; 68: 222-227
116. Tzanakis I, Pras A, Kounali D et al. Mitral annular calcifications in haemodialysis patients: A possible protective role of magnesium. Nephrol Dial Transplant 1997.; 12: 2036-2037
117. Tzanakis I, Virvidakis K, Tsomi A et al. Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res 2004.; 17: 102-108
118. Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007.; 20: 237-244
119. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009.; 13: 453-459
120. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984.; 231: 1-8
121. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005.; 16: 2495-2500
122. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010.; 25: 187-191
123. Riser BL, Barreto FC, Rezg R et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011.; 26: 3349-3357
124. O'Neill WC, Lomashvili KA, Malluche HH et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011.; 79: 512-517
125. Schiffer E, Liabeuf S, Lacroix C et al. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens 2011.; 29: 783-790
126. Pasch A, Farese S, Graber S et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012.; 23: 1744-1752